Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
We value your privacy
We use cookies to improve your browsing experience, analyse traffic and, with your consent, personalise content. You can accept, reject or customise your choices.
Cookie preferences
Enable or disable cookie categories. Strictly necessary cookies are always active.
Strictly necessary
Essential for the website to function (navigation, security, session). They cannot be disabled.
Functional
Improve usability: remembering language, region and your preferences.
Statistics
Help us understand how the site is used (page views, audience) to optimise it.
Marketing
Allow relevant advertising to be shown and campaigns to be measured.
